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ABSTRACT
Ellipticine is an antineoplastic agent, whose mode of action is based mainly on DNA intercalation, inhibition of topoisomerase II 
and formation of covalent DNA adducts mediated by cytochromes P450 and peroxidases. Here, the cytotoxicity of ellipticine to 
human neuroblastoma derived cell lines IMR-32 and UKF-NB-4 was investigated. Treatment of neuroblastoma cells with ellipticine was 
compared with that of these cancer cells with doxorubicin. The toxicity of ellipticine was essentially the same as that of doxorubicin to 
UKF-NB-4 cells, but doxorubicin is much more effective to inhibit the growth of the IMR-32 cell line than ellipticine. Hypoxic conditions 
used for the cell cultivation resulted in a decrease in ellipticine and/or doxorubicin toxicity to IMR-32 and UKF-NB-4 neuroblastoma cells. 
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agents (cyclophosphamide, ifosfamide, melphalan), topoi-
somerase II inhibitors (etoposide), anthracycline antibiotics 
(doxorubicin) and vinca alkaloids (vincristine). Some novel 
regimen include also topoisomerase I inhibitors (topotecan 
and irinotecan), which have been found to be effective 
against recurrent disease (Brodeur, 2003). 
Ellipticine  (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) 
and several of its more soluble derivatives exhibit significant 
antitumor and anti-HIV activities (Stiborová et al., 2001) . 
The main reason for the interest in ellipticine and its deriva-
tives for clinical purposes is their high efficiencies against 
several types of cancer (Auclair, 1987). Nevertheless, ellip-
ticine is a potent mutagen (for an overview, see Stiborová et 
al., 2001). Ellipticine is an agent which cause DNA damage 
by several modes of action. Intercalation and/or inhibition 
of topoisomerase II was thought to be the major mecha-
nism of ellipticine action. These mechanisms of action do 
not however, explain the ellipticine selectivity to several 
cancer diseases. Recently we have showed that ellipticine 
also covalently binds to DNA after being enzymatically 
activated (Stiborová et al., 2001; Frei et al., 2002; Stiborová et 
al., 2003a; Stiborová et al., 2003b). Human cytochrome P450 
(CYP) enzymes, CYP3A4, 1A1, and 1B1–enzymes, which are 
expressed in tumors sensitive to ellipticine (i.e., breast can-
cer; Murray et al., 1993), were found to be the most efficient 
CYPs activating ellipticine to form covalent DNA adducts 
(Stiborová et al., 2001). The formation of these adducts was 
also detected in V79 lung fibroblast cells transfected with 
human CYP3A4, 1A1, and 1A2 (Frei et al., 2002), in human 
Introduction
Neuroblastoma is the most frequent solid extra cranial tumor 
in children and is a major cause of death from neoplasia in 
infancy (Maris and Mathay, 1999). These tumors are biologi-
cally heterogeneous, with cell populations differing in their 
genetic programs, maturation stage and malignant potential 
(Brodeur, 2003). On the one hand, low risk neuroblastoma is 
one of the rare human malignancies known to demonstrate 
spontaneous regression from an undifferentiated state to a 
completely benign cellular formation (ganglioneuromas). On 
the other hand, high risk neuroblastoma grows relentlessly 
and may be rapidly fatal (Brodeur, 2003). Prognosis of high 
risk tumors is poor, because drug resistance arises in the 
majority of those patients, initially responding to chemo-
therapy, in spite of the intensive therapy including megath-
erapy with subsequent hematopoietic progenitor cell trans-
plantation, biotherapy and immunotherapy (Brodeur, 2003). 
Chemotherapy agents used in combination have been 
found to be effective against neuroblastoma. Agents com-
monly used are platinum compounds (carboplatin), alkylating 
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breast adenocarcinoma MCF-7 cells (Borek-Dohalská et al., 
2004), and in vivo in rats exposed to ellipticine (Stiborová et 
al., 2003b). On the basis of these data, ellipticine might be 
considered a drug whose pharmacological efficiencies and/
or genotoxic side effects are dependent on its enzymatic 
activation in target tissues (Stiborová et al., 2001; Frei et al., 
2002; Stiborová et al., 2003a; Stiborová et al., 2003b; Borek-
Dohalská et al., 2004). 
Some improvement in therapeutic options of neurobla-
soma has been made in the last decade, but there is still the 
need for the development of new therapies. Therefore, the 
present study was undertaken to investigate the cytotoxicity 
of ellipticine on human neuroblastoma cell lines and to 
compare the cytotoxicity of ellipticine with that of doxo-
rubicin to these cancer cells. Another aim of the study was 
to evaluate the effect of hypoxia on cytotoxicity produce by 
both agents.
Material and methods
Chemicals 
Ellipticine  was  obtained  from  Sigma  (St.  Louis,  MO, 
USA). Doxorubicin was obtained from EBEWE Pharma 
Ges.m.b.H. (Uunterach, Austria). All other chemicals used 
in the experiments were of analytical purity or better. 
Cell cultures
The UKF-NB-4 neuroblastoma cell line, established from 
bone  marrow  metastases  of  high  risk  neuroblastoma, 
was a gift of prof. J. Cinatl, Jr. (J. W. Goethe University, 
Frankfurt, Germany). Cell line UKF-NB-4 was established 
from infiltrated bone marrow of chemoresistant high risk 
neuroblastoma recurrency. IMR-32, high risk neuroblas-
toma derived cell line, was of the commercial source (LGC 
Promochem, Wesel, Germany). Both used cell lines were 
derived from a high risk neuroblastoma with MYCN ampli-
fication. The doxorubicin and/or ellipticine resistant cell 
sublines designated IMR-32 (DOXO), UKF-NB-4 (DOXO) 
and UKF-NB-4 (Elli) were established by incubation of 
parental cells with increasing concentrations of respective 
drug by the procedure as described (Kotchetkov et al., 2003). 
Cells were grown at 37 °C and 5% CO2 in Iscove’s modified 
Dulbecco’s medium (IMDM) (KlinLab Ltd, Prague, Czech 
Republic), supplemented with 10% fetal calf serum, 2 mM 
L-glutamine,  100  units/ml  of  penicilline  and  100 µg/ml 
streptomycine (PAA Laboratories, Pasching, Austria). For 
hypoxia experiments, cells were maintained in modular 
incubator chamber (Billups-Rothenberg Inc., Del Mar, CA, 
USA) flushed with 1% O2, 5% CO2 and balance N2 for 4 min 
(hereafter refered to as hypoxia). This chamber was placed 
into 37 °C. 
MTT assay
The cytotoxicity of ellipticine and doxorubicin was deter-
mined by MTT test. For a dose-response curve, DMSO 
stock solutions of ellipticine (10 mM) and aqueous solutions 
of doxorubicin (1 mM) were dissolve in culture medium 
to final concentrations of 0–50 µM were added. Cells in 
exponential growth were seeded at 1 × 104 per well in a 
96-well plate. Briefly, after incubation (96 hours) at 37 °C in 
5% CO2 saturated atmosphere the MTT solution (2 mg/ml 
PBS) was added, the plates were incubated for 4 hours and 
cells lysed in 50% N,N-dimethylformamide containing 20% 
of SDS pH 4.5. The absorbance at 570 nm was measured for 
each well by multiwell ELISA reader Versamax (Molecular 
devices, CA). The mean absorbance of medium controls 
was the background and was subtracted. The absorbance 
of control cells was taken as 100% viability and the values 
of treated cells were calculated as a percentage of control. 
Each value is the mean of 8 wells with standard deviation. 
The IC50 values were calculated from the linear regression 
of the dose-log response curves by SOFTmaxPro.
Flow cytometry
Cells were harvested by trypsinization and washed with 
PBS. FITC labeled antibody against ABCB1 (anti P-gp FITC, 
Immunotech) was added and samples were incubated for 
15 minutes at room temperature. After washing with PBS 
the cells were resuspended in PBS and analyzed by flow 
cytometry FACSCalibur (BD).
Results
Cytotoxicity of ellipticine to human neuroblastoma cells
To  determine  the  cytotoxicity  of  ellipticine  to  human 
neuroblastoma cells, these cells were treated with increas-
ing concentrations of ellipticine. We first determined the 
effect of ellipticine on growth of human neuroblastoma cell 
lines (IMR-32 and UKF-NB-4) cultured for 96 h in the pres-
ence of ellipticine, using MTT assay. As shown in Figure 1, 
both neuroblastoma cell lines were sensitive to ellipticine. 
Table 1. 
Cytotoxicity of ellipticine and doxorubicin to neuroblastoma cell lines. 
cells ic50  (µM)
for ellipticine for doxorubicin
IMR-32 0.27 ± 0.02 0.02 ± 0,01
IMR-32  
(hypoxic conditions) 0.43 ± 0.02 not measured
IMR-32 (DOXO) 0.53 ± 0.03 0.03 ± 0.01
UKF-NB-4 0.44 ± 0.03 0.70 ± 0.07
UKF-NB-4  
(hypoxic conditions) 0.77 ± 0.03 1.61 ± 0.08
UKF-NB-4 (DOXO) 1.14 ± 0.07 3.80 ± 0.38
UKF-NB-4 (Elli) 1.17 ± 0.07 0.70 ± 0.07
UKF-NB-4 (Elli)  
(hypoxic conditions) 1.57 ± 0.14 1.51 ± 0.08
IC50 values were calculated from the linear regression of the dose-log 
response curves after 96 h exposure to the compound, determined by 
the MTT assay. Values are mean ± S.D. of at least 3 experiments. 188
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Cytotoxicity of ellipticine was compared with that of doxo-
rubicin, one of the drugs currently used for neuroblastoma 
treatment (Table 1). Besides the effects of ellipticine or 
doxorubicin to these parental neuroblastoma cell lines, 
derived daughter neuroblastoma lines that were resistant to 
doxorubicin were also investigated. Ellipticine and doxoru-
bicin inhibited the growth of neuroblastoma cell lines in a 
dose-dependent manner. The IC50 values for ellipticine and 
doxorubicin calculated from the dose-log response curves 
are shown in Table 1. The toxicity of ellipticine to UKF-NB-4 
cells was analogous to that of doxorubicin to these cell lines, 
while IMR-32 cells were much more sensitive to the treat-
ment with doxorubicin than with ellipticine (see IC50 values 
shown in Table 1). 
A decrease in the viability induced by ellipticine and/or 
doxorubicin in the parental cell lines was compared with 
that in their variants resistant to doxorubicin. Interestingly, 
a decrease in sensitivity of the doxorubicin-resistant lines 
to ellipticine was significantly lower than a decrease in sen-
sitivity of these lines to doxorubicin (Table 1), even though 
the cross-resistance would be expectable (Kotchetkov et 
al., 2003). In the case of the UKF-NB-4 cell line, the IC50 
value for ellipticine in UKF-NB-4 (DOXO) was only 2.6-fold 
higher than that in the parental UKF-NB-4 cell line, whereas 
the IC50 value of doxorubicin increased by 5.4-fold in the 
doxorubicin resistant cell line.
Ellipticine induces resistance to this compound in neuroblastoma cells 
In order to evaluate the potential of ellipticine to induce the 
resistance of neuroblastoma cells to this drug, one of the cell 
lines, UKF-NB-4, was incubated 36 months with increasing 
concentrations of ellipticine (1–2.5 µM). A 2.6-fold increase 
in the IC50 value for ellipticine was found (Table 1, Figure 1). 
The induction of resistance of the UKF-NB-4 cell line to 
ellipticine is not mediated by P-glycoprotein, a member of 
ABC transporters (Figure 2). 
Ellipticine resistance of UKF-NB-4 is not mediated by P-glycoprotein
Lower cytotoxicity of doxorubicin to UKF-NB-4 (DOXO) 
than  to  UKF-NB-4  is  caused  by  higher  expression  of 
P-glycoprotein in a membrane of the doxorubicin resistant 
cell line. In contrast to these results, the IMR-32 (DOXO) cell 
line expresses P-glycoprotein at the same level as parental 
IMR-32 line. The UKF-NB-4 cell line resistant to ellipticine 
also does not express P-glycoprotein in the higher levels than 
the parental cell line. Resistance to ellipticine is therefore 
mediated by another mechanism of action. The study resolv-
ing this mechanism is under the way in our laboratories.
Hypoxia decreases the toxicity of ellipticine and doxorubicin
Hypoxia was found in most tumor malignancies. To deter-
mine the effect of hypoxia on the cytotoxicity of ellipticine 
and/or doxorubicin to IMR-32, UKF-NB-4 and daughter 
cells resistant to doxorubicin, the cells were treated with 
increasing  concentrations  of  either  cytostatics  for  96 h 
under hypoxic conditions and analyzed using MTT assay. 
As shown in Table 1, all neuroblastoma cell lines were less 
sensitive to applied cytostatics under the hypoxic conditions 
of their cultivation. 
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Figure 1. Cytotoxicity (viable cells as percentage of control) of ellipti-
cine to IMR-32 (A), UKF-NB-4 and UKF-NB-4 cells resistant to ellipticine   
(UKF-NB-4Elli) (B) after 96 h exposure to the compound, determined 
by the MTT assay. Values are means of 8 determinations. Standard 
deviation was ≤ 10%. 
Figure 2. Levels of P-glycoprotein expressed as mean fluorescence 
intensity in neuroblastoma derived cell lines.189
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Discussion
The results of this study show that ellipticine is cytotoxic 
to human neuroblastoma cell lines (both to the parental 
IMR-32 and UKF-NB-4 lines and their variants resistant to 
doxorubicin), inhibiting the growth of these cancer cells. 
Hypoxia frequently occurs in tumors because of their 
fast  growth  and  inadequate  vascularisation.  It  strongly 
correlates with advanced disease and poor outcome caused 
by chemoresistance. The cytotoxicity of ellipticine or doxo-
rubicin decreased when neuroblastoma cells were cultivated 
and treated with these agents under the limited concentra-
tion of oxygen. 
Because drug resistance is general feature of neuro-
blastoma, and arises in the majority of patients suffering 
from this cancer, we also investigated whether ellipticine is 
capable of inducing resistance in neuroblastoma cells. The 
UKF-NB-4 cell line was used for such a study. The results 
demonstrate that ellipticine might, to some extent, induce 
the drug resistance in these cells. Long-term treating this 
cancer line with increasing concentrations of ellipticine 
resulted in the morphological changes in the ellipticine-
resistant cell line (not shown). The decrease in sensitivity 
of this cell line to ellipticine was, however, lower than that 
in sensitivity of the doxorubicin-resistant UKF-NB-4 cell 
line to doxorubicin. The doxorubicin-induced resistance 
of these neuroblastoma cells resulted in more than 5-times 
higher decrease in sensitivity of neuroblastoma to this drug. 
Moreover, the IC50 values for ellipticine in the ellipticine-
resistant neuroblastoma cell line is, even under the hypoxic 
conditions, still one order of magnitude lower than the 
ellipticine levels in blood in mice, 4 hours after their p.o. 
treatment with ellipticine in a tolerable dose (Hardesty et 
al., 1972). The study resolving the reasons of the changes 
found in the ellipticine-resistant neuroblastoma cells on 
the molecular levels is under way in our laboratories. The 
changes in the genetic programs in this cell line after induc-
tion of resistance to ellipticine are analyzed at the present 
time. Our experiments suggest that the ellipticine-mediated 
resistance is not dependent on expression of P-glycoprotein 
as it is the case of the UKF-NB-4 cell line resistant to doxo-
rubicin (Bedrníček et al., 2005, present paper). 
The results presented in this paper are the first report 
demonstrating  the  cytotoxicity  of  ellipticine  in  human 
neuroblastoma cells. Another important result of the study 
is  finding  that  ellipticine  can  induce  resistance  to  this 
agent, which is, however, lower than resistance of neuro-
blastoma cells to doxorubicin caused by doxorubicin. This 
finding is the promising result that might be utilized for 
the development of new neuroblastoma therapies, namely, 
for  the  substitution  and/or  combination  of  the  current 
anticancer drugs with ellipticine or its derivatives. For the 
practical use it seems to be important that there is only 
partial cross-resistance between ellipticine and doxorubicin 
in neuroblastoma, which is not caused in all cell lines by 
P-glycoprotein.
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